Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Laura, Iadeluca"'
Publikováno v:
Gynecologic Oncology Reports, Vol 54, Iss , Pp 101440- (2024)
Objective: Previous studies have shown that first-line (1L) maintenance therapy (MT) with poly(ADP-ribose) polymerase inhibitors and/or bevacizumab improves outcomes among patients with advanced ovarian cancer (OC); however, these treatments are unde
Externí odkaz:
https://doaj.org/article/62aca536a8d045baba07fd6e15b603ae
Autor:
Yi-Long Wu, MD, Shun Lu, MD, PhD, James Chih-Hsin Yang, MD, PhD, Jianying Zhou, MD, Takashi Seto, MD, Myung-Ju Ahn, MD, PhD, Wu-Chou Su, MD, Noboru Yamamoto, MD, PhD, Dong-Wan Kim, MD, PhD, Jolanda Paolini, MSc, Tiziana Usari, BSc, Laura Iadeluca, PhD, Keith D. Wilner, PhD, Koichi Goto, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 10, Pp 100406- (2022)
Introduction: Crizotinib provided meaningful clinical benefit in the initial analysis of a phase 2 study in East Asian patients with advanced ROS1-positive NSCLC (NCT01945021). Nevertheless, overall survival (OS) data were immature. Here, we present
Externí odkaz:
https://doaj.org/article/7369e36175e44454b80a3ac673b3634f
Publikováno v:
Applied Health Economics and Health Policy. 21:661-672
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::16d3d355a516ce585ac6f73c11d84e90
https://doi.org/10.1007/s40258-023-00807-7
https://doi.org/10.1007/s40258-023-00807-7
Autor:
Benjamin J, Solomon, Todd M, Bauer, Tony S K, Mok, Geoffrey, Liu, Julien, Mazieres, Filippo, de Marinis, Yasushi, Goto, Dong-Wan, Kim, Yi-Long, Wu, Jacek, Jassem, Froylán López, López, Ross A, Soo, Alice T, Shaw, Anna, Polli, Rossella, Messina, Laura, Iadeluca, Francesca, Toffalorio, Enriqueta, Felip
Publikováno v:
The Lancet Respiratory Medicine. 11:354-366
After a median follow-up of 18·3 months, the third-generation anaplastic lymphoma kinase (ALK) tyrosine-kinase inhibitor, lorlatinib, improved progression-free survival in patients with treatment-naive, ALK-positive non-small-cell lung cancer in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c30ab31bbb51ec67da568ccb47968f7
https://doi.org/10.1016/s2213-2600(22)00437-4
https://doi.org/10.1016/s2213-2600(22)00437-4
Autor:
Yasushi Yatabe, MD, PhD, Yasumasa Yoshiki, MPH, Koichi Matsumura, PhD, Kanae Togo, MSc, Hironori Kikkawa, PhD, Laura Iadeluca, PhD, MPH, Benjamin Li, PhD, Kazuto Nishio, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100136- (2021)
Introduction: Diagnostic testing is important in determining appropriate treatment for individuals with lung cancer. In 2018, testing of five biomarkers (EGFR, ALK, ROS1, BRAF, programmed cell death-ligand 1 [PD-L1]) was approved in Japan. Informatio
Externí odkaz:
https://doaj.org/article/32ccbf8e9d9347f381ea1ab2194febed
Autor:
Gabriel Tremblay, Michael Groff, Laura Iadeluca, Patrick Daniele, Keith Wilner, Robin Wiltshire, Lauren Bartolome, Tiziana Usari, Joseph C Cappelleri, D Ross Camidge
Publikováno v:
Future Oncology. 18:2063-2074
Aims: To compare clinical trial results for crizotinib and entrectinib in ROS1-positive non-small-cell lung cancer and compare clinical trial data and real-world outcomes for crizotinib. Patients & methods: We analyzed four phase I–II studies using
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf36956917d8b19b7d78def4744a70bc
https://doi.org/10.2217/fon-2021-1102
https://doi.org/10.2217/fon-2021-1102
Autor:
Toshiaki Takahashi, Makoto Nishio, Kazumi Nishino, Yasumasa Yoshiki, Naoko Shiraiwa, Birol Emir, Laura Iadeluca, Yasushi Yatabe, Kazuto Nishio
Publikováno v:
Cancer Science.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62bd52d2bb2282c883b5297235ffd177
https://doi.org/10.1111/cas.15752
https://doi.org/10.1111/cas.15752
Autor:
David Waterhouse, Laura Iadeluca, Sneha Sura, Keith Wilner, Birol Emir, Stan Krulewicz, Janet Espirito, Lauren Bartolome
Publikováno v:
Targeted Oncology
Background Crizotinib was the first oral targeted therapy approved by the US Food and Drug Administration (FDA), on 11 March 2016, for c-ros oncogene 1 (ROS1)-positive advanced non-small-cell lung cancer (NSCLC). Data to support long-term clinical be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52738acf64628ec57dfcffa772cc8015
http://europepmc.org/articles/PMC8783880
http://europepmc.org/articles/PMC8783880
Autor:
Julien Mazieres, Laura Iadeluca, Alice T. Shaw, Benjamin J. Solomon, Todd M. Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Dong-Wan Kim, Tony Mok, Arlene Reisman, Holger Thurm, Anna M. Polli, Geoffrey Liu
Publikováno v:
Scientia
Crizotinib; Lorlatinib; Patient-reported outcomes Crizotinib; Lorlatinib; Resultados informados por el paciente Crizotinib; Lorlatinib; Resultats informats pel pacient Objectives Quality of life (QoL) for patients with non-small cell lung cancer (NSC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11f8ee8423e1525c66c4f381ecd9f392
https://hdl.handle.net/11351/8574
https://hdl.handle.net/11351/8574
Publikováno v:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
This study aimed to compare the relative efficacy of lorlatinib, an anaplastic lymphoma kinase-tyrosine kinase inhibitor, with chemotherapy, for patients with second-line or later advanced anaplastic lymphoma kinase-positive non-small cell lung cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::545b9ce100c31f6f3ed91a5e1e10208b
https://pubmed.ncbi.nlm.nih.gov/35985941
https://pubmed.ncbi.nlm.nih.gov/35985941